Currently, sipuleucel-T, the first personalized DC vaccine for prostate cancer, has been approved by the U.S. Food and Drug Administration, but the clinical outcomes were generally poor, possibly due to the insufficient induction of CD8+ CTL responses. This evidence concerns the gene CD8A and prostate cancer.